Research Ethics Committee Reference Number	Full Name of Trial	Date of Receipt of Valid Research Application	Date of First Patient Recruited	Reasons for not achieving the 70 day target from receipt of valid research application to 1st patient recruited										Comments	Reasons for delay correspond to:
				A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other		
13/LO/1595	COgnitive behavioural therapy vs standardised medical care for adults with Dissociative non-Epileptic Seizures: A multi-centre randomised controlled trial (CODES).	17/10/2014	12/11/2014											70 day target met	Neither
14/LO/1381	Reformulated raltegravir q.d. (1200 mg) versus raltegravir b.i.d. (400 mg) in ART-naïve pts (ONCE)	22/10/2014	13/11/2014											70 day target met. Recruitment target of 5 met.	Neither
14/ES/0072	How can we optimise inhaled beta2 agonist dose as 'reliever' medicine for wheezy pre-school children.	15/10/2014	13/03/2015							Y				As at end of September there were >10 screened, but most ineligible or declined. First patient recruited 13.3.15	Neither
13/LO/0699	Evaluating the effects of novel GLP-1 analogue, liraglutide, in patients with Alziemer's disease (ELAD study)	30/10/2014	24/03/2015					Y	Y					Difficult to find patients with early AD. PI on extended leave Dec14/Jan15	NHS Provider
13/YH/0147	A randomized, Open Label, Multi-Centre, Controlled Study to Assess Safety and efficacy of ELAD in subjects with Acute Alcoholic Hepatitis (AAH) Who have failed Steroid Therapy (incorporating VTI-210E as a follow up registry)	12/11/2014	N/A						Y					Difficult recruitment criteria. Patients not eligible. Study closed to recruitment 21/8/15	Neither
14/LO/1513	A Randomized, Open Label, Phase 4 Study Evaluating the Renal Effect of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF or other Tenofovir DF-containing Regimens (Ritonavir-boosted Atazanavir plus Emtricitabine/Tenofovir DF or Efavirenz /Emtricitabine/Tenofovir DF) compared to Ritonavir boosted Atazanavir plus Abacavir/Lamivudine in Antiretroviral Treatment-naïve HIV-1 Infected Adults with eGFR ≥70 mL/min	23/10/2014	05/02/2015				Y		Y					Memo dated 20/11/14 refers to sponsor delay due to drug supply. First patient screened 5/1/2015 but failed screen on viral load. FPR 5.2.15.	Sponsor
14/WM/0083	A Phase III Trial of Surgery versus Active Monitoring for Low Risk Ductal Carcinoma in Situ (DCIS) (LORIS)	01/10/2014	09/09/2015	Y			Y			Y	Y			Site activation delayed post-SIV as no contract was in place. Once this was resolved, the Sponsor issued an amendment, so recruitment could not commence until the amendment was processed and given all relevant approvals. Amendment approved 6th Jan 2015. First patient recruited 9/9/15	Both
11/NW/0548	RIAltO: A Randomised Investigation of Alternative Ofatumumab-containing regimens in less fit patients with CLL	13/10/2014	09/09/2015						Y					First patient recruited 9/9/15. Prior to this, every effort was made to recruit to this study. 7 patients screened (not eligible), then the study was put on on hold due to drug supply issues. These issues arose after the FPR date, so did not affect the target not being achieved.	Neither
12/LO/1109	A Prospective Randomised Phase III Study of Observation Versus Screening MRI And Pre-Emptive Treatment in Castrate Resistant Prostate Cancer Patients With Spinal Metastasis	17/10/2014	09/12/2014											70 day target met	Neither
13/SC/0111	FOCUS4 – Molecular selection of therapy in colorectal cancer: a molecularly stratified randomised controlled trials programme	24/10/2014	N/A	Y			Y							Delays with sending/completing study documentation meant we were unable to commence recruitment until Jan 2015. Screened many but not recruited. Reduced target figures and changed method of screening but still no eligible patients	Both
14/LO/0298	A multicenter, Single Arm Study of Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate.	30/10/2014	25/11/2014											70 day target met.	Neither
14/LO/1052	A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety andEfficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, forPatients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant AndrogenDeprivation Therapy With External Beam Radiation Therapy (EBRT)	18/11/2014	06/01/2015											70 day target met	Neither
14/EM/1070	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Evaluating the Safety and Efficacy of Icatibant as a Treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Angioedema in Adults	22/12/2014	10/03/2015									Y		Rare disease type, but only missed 70 day target by 8 days.	Neither
14/YH/0088	Phase I study of KHK2823 in Patients with Acute Myeloid Leukaemia or Myelodysplastic Syndrome	17/12/2014	29/04/2015				Y							The principle reason for lack of recruitment is study design. It is a cohort study, and patient slots have to be reserved for identified patients before consent and screening can occur. We have identified 3 potential patients for this study, the first in January 2015, but due to competing sites and safety issues we were not been given a cohort slot until April 2015.	Sponsor
13/YH/0394	Multi-centre Randomised Controlled Trial of Angiotensin Converting Enzyme inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) withdrawal in adncace renal disease: The STOP-ACEi Trial	14/10/2014	14/11/2014											70 day target met	Neither
14/YH/0086	RESPOND: Repositionable Lotus Valve System-Post Market Evaluation of Real World Clinical Outcomes	06/10/2014	22/10/2014											70 day target met	Neither
14/SC/1161	Prospective, single-arm, Multi-centre, observational registry to Further Validate Safety and Efficacy of the Ultimaster DES system in unselected patients representing everyday clinical practice	18/12/2014	22/12/2014											70 day target met	Neither
14/WM/0013	A Randomized, Double blind, Placebo-Controlled, 2-Part Study of Orally Administered ALS-008176 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dosing and Multiple Ascending Dosing in Infants Hospitalized with Respiratory Syncytial Virus (RSV) Infection.	19/12/2014	N/A				Y		Y					IMP not received until 7/1/15 (sponsor delay). No eligible patients as at 30/9/15 - nil meeting inclusion criteria	Sponsor
13/LO/1891	More Response on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP)	04/11/2014	07/01/2015											70 day target met	Neither
13/LO/0145	A multicentre phase III randomised controlled single masked clinical trial to test the clinical efficacy of LightMasks at preventing dark adaptation in the treatment of early diabetic macular oedema (CLEOPATRA)	09/01/2015	25/03/2015					Y						Research Nurse retired and there has been a delay in recruiting a replacement which has caused delays with recruitment. Missed 70 deadline by 5 days.	NHS Provider
14/LO/0203	Clinical Efficacy and Mechanistic Evaluation of Aflibercept for Proliferative Diabetic Retinopathy.A Multicentre Phase IIb	08/01/2015	10/06/2015					Y						Research Nurse retired and there has been a delay in recruiting a replacement which has caused delays with recruitment	NHS Provider
12/NW/0361	A pragmatic randomised controlled trial comparing the effectiveness and cost effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of Standard And New Antiepileptic Drugs (SANAD-II)	19/01/2015	03/03/2015											70 day target met	Neither
14/LO/1443	A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Subjects on Stable Dialysis	19/01/2015	N/A				Y							15 patients approached but all declined. One patient consented 4/3/15, but within days of randomisation the Sponsor said they were not included because they could not get hold of the required dose of the drug. Still no patients recruited as at 30.9.15	Sponsor
09/H0709/56	Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytlplasm Antibody Associated Vasculitis: an international Randomised Controlled Trial	13/01/2015	26/01/2015											70 day target met	Neither

13/NE/0336	A randomised, placebo controlled trial of extraoesophageal reflux treatment in the management of upper respiratory symptoms. [TOPPITS: Trial of Proton Pump Inhibitors in Throat Symptoms]	04/02/2015	08/04/2015											70 day target met	Neither
14/LO/1435	A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel® in Subjects With Rheumatoid Arthritis and Inadequate Response to Treatment With Methotrexate	12/02/2015	N/A			Y			Y					Closed early by Sponsor when global recruitment target was met. Closure was 2.5 weeks in advance of the FPR target date.	Sponsor
14/LO/0117	Ablation Versus Anti-arrhythmic Therapy for Reducing All Hopital Episodes from Recurrent Atrial Fibrilation	17/02/2015	24/04/2015											70 day target met	Neither
14/LO/1493	A phase IV open-label, multi-centre, randomised, dual-arm, pilot study to assess the feasibility of switching individuals receiving Efavirenz with continuing Central Nervous System (CNS) toxicity, to Dolutegravir	06/01/2015	23/01/2015											70 day target met	Neither
13/SC/0638	Human papillomavirus infection: a randomised controlled trial of Imiquimod cream (5%) versus Podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac Trial)	20/01/2015	06/03/2015											70 day target met	Neither
13/YH/0315	A randomized, parallel group, open-label, multicentre study to investigate the efficacy and safety of oral BAY 85-3934 and active comparator (darbepoetin alfa) in the maintenance treatment of anemia in pre-dialysis subjects with chronic kidney disease on darbepoetin treatment in Europe and Asia Pacific.	25/02/2015	N/A						Y					Difficult recruitment criteria. Patients not eligible. Recruitment closed by sponsor 10/6/15.	Neither
13/WA/0004	Oral steroids for the resolution of otitis media in children study (OSTRICH)	04/02/2015	N/A							Y				Difficult study to recruit to. No parent willing to put their child on steroids. All opted for surgery as preferential route. Following talks with main site, PI closed site to recruitment.	Neither
14/LO/1043	A Multicentre Phase III Doublemasked Randomised Controlled NonInferiority Trial comparing the clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for or Macular Oedema due to Central Retinal Vein Occlusion (CRVO).	30/03/2015	22/04/2015											70 day target met	Neither
13/LO/1115	UK Multicentre Open-label Randomised Controlled Trial Of IV Iron Therapy In Incident Haemodialysis Patients	08/04/2015	30/04/2015											70 day target met	Neither
11/SS/0100	A multicentre randomised trial to establish the effect(s) of routine administration of Fluoxetine in patients with recent stroke	21/04/2015	03/06/2015											70 day target met	Neither
11/NE/0228	IoN- Is ablative radioidoine Necessary for low risk throid cancer patients	15/04/2015	N/A				Y			Y				Site activation delayed by 65 days post-SIV because the Sponsor required further information. Site activation 22/6/15. Difficult recruitment criteria mean that only 1 eligible patient has been identified, and that patient declined.	Both
13/LO/1463	InterAACT- An International MultiCentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-fluorouracil versus Carboplatin plus weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease.	23/04/2015	06/05/2015											70 day target met	Neither
14/SS/1048	A Phase 3b, Multi-center, Randomized-withdrawal, Placebo-controlled, Double blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45 to 120 mg/day, Split-dose) in Subjects with Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease	01/05/2015	26/05/2015											70 day target met	Neither
13/NI/0188	A single-arm trial to evaluate the effectiveness of PCI of de novo 3-vessel disease applying the SYNTAX Score II with pressure wire functional assessment and IVUS guidance, using an everolimus-eluting stent with biodegradable abluminal coating	05/05/2015	28/05/2015											70 day target met	Neither
13/YH/0229	GO2: A phase III, randomised, multi-centre, prospective, controlled open-label, non-inferiority trial of alternative chemotherapy for frail and elderly patients with advanced gastric or oesophageal cancer.	12/05/2015	27/07/2015						Y					Missed 23.7.15 FPR target by 4 days	Neither
14/WM/1210	A Phase 3, randomized, active-controlled, open-label study to evaluate the efficacy, safety and tolerability of switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once-daily single-tablet regimen versus continuing the current regimen consisting of a boosted protease inhibitor (bPI) combined with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in virologically-suppressed, human immunodeficiency virus type 1 (HIV-1) infected subjects.	03/06/2015	22/06/2015											70 day target met	Neither
11/SC/0528	A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with locally advanced cervical cancer	09/06/2015	24/09/2015						Y					No suitable patients found in 70 day window. First patient recruited 24.9.15	Neither
13/SS/0007	A multi-arm, phase 2b randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis.	10/06/2015	05/08/2015											70 day target met	Neither
14/LO/2218	Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer.	19/06/2015	N/A	Y			Y		Y					Delays with recruitment due to being unable to implement an amendment without the green light from the Sponsor about costings. Amendment implementation date was 20/7/15, but approval to proceed not received from Sponsor until 14/8/15.	Sponsor
14/SS/1087	Immediate-release Tolvaptan (OPC 41061, 30 mg to 120 mg/day, Split dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease	24/06/2015	14/07/2015											70 day target met.	Neither
14/NE/1185	Short duration of dual antiplatElet therapy with SyNergy® II everolimus eluting stent in patients Older than 75 years undergoing percutaneous coronary Revascularization. The SENIOR trial	01/07/2015	28/08/2015											70 day target met	Neither
15/YH/0045	ABLATOR Ablation Observational Registry	08/07/2015	03/08/2015											70 day target met	Neither
13/NI/0138	Portic I study International long-term follow-up study of patients	08/07/2015	24/08/2015											70 day target met	Neither
14/YH/1269	Open-label evaluation of the population pharmacokinetic profile, safety, tolerability, and efficacy of intravenous tapentadol solution for injection for the treatment of post-surgical pain in children aged from birth to less than 2 years, including preterm neonates	08/07/2015	N/A							Y				2 patients screened, however both declined. The study is behind target nationally.	Neither
15/LO/0684	Effects of ODM-109 on respiratory function in patients with ALS. A randomised, double blind, placebo-controlled, cross-over, 3-period.	13/07/2015	N/A					Y	Y					Patient consented into trial 16.9.15, but failed screening. PI also unavailable for one month when study open due to having an operation.	NHS Provider
15/LO/0075	A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily plus Ritonavir 100 mg Once Daily, Each in Combination with TRUVADA™ or EPZICOM™/KIVEXA™, in Treatment-Naive HIV-1 Infected Subjects	27/07/2015	10/08/2015											70 day target met	Neither

13/LO/1207	StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): A randomised, double-masked, sham-controlled, clinical trial comparing low-voltage X-ray irradiation with as needed bevacizumab, to as needed bevacizumab monotherapy.	27/07/2015	07/10/2015				Y								Sponsor delays mean site wasn't activated until 21 September 2015. First available clinic capacity was 07/10/15. 70-day target missed by 2 days.	Sponsor
14/NW/1531	Comparative Testing of 3 mL TransFix/EDTA Vacumm Blood Collection Tubes (TVTs) and Cyto-Chex 5 mL Blood Collection Tubes (BCTs) Part 1: Equivalence Study	06/08/2015	24/08/2015												70 day target met	Neither
13/EE/0335	COOL-AMI EU CASE SERIES CLINICAL STUDY: a single-centre case series clinical study to assess the feasibility of integrating therapeutic hypothermia(TH)using the ZOLL IVTM System as an adjuvant therapy in percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI)	26/08/2015	N/A												Still within target timeframe	Neither
14/WM/0057	Multi-centre randomised controlled trial to compare the clinical and cost-effectiveness of a 'vein bypass first' with a 'best endovascular first' revascularisation strategy for severe limb ischemia due to infra-popliteal arterial disease: Bypass vs. Angioplasty in Severe Ischemia of the Leg.	19/08/2015	N/A												Still within target timeframe	Neither
15/SC/0280	Randomised Evaluation of dabigatran etexilate Compared to warfarIn in pulmonaRy vein ablation: assessment of an uninterrupted periproCedUral anticoagulation sTrategy (The RE-CIRCUIT Trial)	25/08/2015	N/A												Still within target timeframe	Neither
15/LO/0963	Assessing the reliability and validity of using ultrasound scanning to determine muscle morphology and geometry of the lumbar spine	26/08/2015	N/A												Still within target timeframe	Neither
13/EM/0459	POSNOC – Positive Sentinel Node: adjuvant therapy ale versus adjuvant therapy plus Clearance or axillary radiotherapy. A randomised controlled trial of axillary treatments in women with early stage breast cancer who have metastases in one or two sentinel nodes.	31/08/2015	N/A												Still within target timeframe	Neither
14/SC/1030	A randomised controlled trial to compare the clinical effectiveness and safety of gentamicin and ceftriaxone in the treatment of gonorrhoea.	14/09/2015	N/A												Still within target timeframe	Neither
15/LO/0881	A Phase III Multicenter, Double Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evluate the Safety and Efficacy of MK-149A One Daily Versus ATRIPLA Once-Daily in Treatment Naïve HIV - 1 Infected Subjects	28/09/2015	N/A												Still within target timeframe	Neither
15/NW/0505	A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs)	28/09/2015	N/A												Still within target timeframe	Neither